SGLT1-sparing oral SGLT2 inhibitor prodrug
launched in India for diabetes, 100 mg BID
from mouse urine drug metabolite and opt.
Bioorg. Med. Chem., Jan. 22, 2021
Kissei Pharma / Toho University, JP
The Kissei SGLT2 inhibitor prodrug, remogliflozin etabonate, is an SGLT1-sparing oral drug launched in 2019 in India for the treatment of type 2 diabetes. Interestingly, the lead for this drug was a metabolite identified from mouse urine after treatment with a Wyeth-Ayerst antihyperglycemic agent of previously unknown mechanism.